



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HJC0416 hydrochloride

Cat. No.:	HY-12352A
CAS No.:	2415263-08-8
Molecular Formula:	C ₁₈ H ₁₈ Cl ₂ N ₂ O ₄ S
Molecular Weight:	429.32
Target:	STAT; Apoptosis
Pathway:	JAK/STAT Signaling; Stem Cell/Wnt; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HJC0416 hydrochloride is a potent and orally active STAT3 inhibitor with an enhanced anticancer profile than Stattic (HY-13818). HJC0416 hydrochloride is a promising anti-cancer agent for breast cancer study ^[1] .														
IC₅₀ & Target	STAT3														
In Vitro	<p>HJC0416 hydrochloride inhibits the proliferation of both ER-positive, and ER-negative (triple negative) breast cancer cells with IC₅₀ values of 1.76 μM and 1.97 μM, respectively. However, it displays a marked antiproliferative effect against pancreatic cancer cell line AsPC1 and Panc-1 with IC₅₀ values of 40 nM and 1.88 μM, respectively^[1].</p> <p>HJC0416 hydrochloride (1-10 μM; 48 hours) inhibits cell growth and induced apoptosis accompanying cellular morphological changes in MDA-MB-231 breast cancer cells^[1].</p> <p>HJC0416 hydrochloride (5 μM; 24 hours) decreases the STAT3 promoter activity by approximately 51%, while stattic (HY-13818) only decreases the STAT3 promoter activity by 39% in MDA-MB-231 cells after transient transfecting with pSTAT3-Luc vector^[1].</p> <p>HJC0416 hydrochloride (1-10 μM; 12 hours) has a comparable potency in downregulating STAT3 protein production and phosphorylation at Tyr-705 site when compares with Stattic (HY-13818). Additionally, it also induces cleaved caspase-3 and downregulated cyclin D1 levels in MDA-MB-231 cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cycle Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>MDA-MB-231 breast cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>1-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Induced cell apoptosis in cancer cells.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>MDA-MB-231 breast cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>1 μM; 5 μM; 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 hours</td> </tr> </table>	Cell Line:	MDA-MB-231 breast cancer cells	Concentration:	1-10 μM	Incubation Time:	48 hours	Result:	Induced cell apoptosis in cancer cells.	Cell Line:	MDA-MB-231 breast cancer cells	Concentration:	1 μM; 5 μM; 10 μM	Incubation Time:	12 hours
Cell Line:	MDA-MB-231 breast cancer cells														
Concentration:	1-10 μM														
Incubation Time:	48 hours														
Result:	Induced cell apoptosis in cancer cells.														
Cell Line:	MDA-MB-231 breast cancer cells														
Concentration:	1 μM; 5 μM; 10 μM														
Incubation Time:	12 hours														

Result:	Decreased p-STAT3 phosphorylation expression and cyclin D1 level.
---------	---

In Vivo

HJC0416 hydrochloride (intraperitoneal injection; 10 mg/kg; 7 days) shows a 67% decrease of tumor volume as compared to the control mice. Similarly, HJC0416 hydrochloride (oral administration; 100 mg/kg; 14 days) also significantly reduces tumor volume at a dose of 100 mg/kg by 46%. The i.p. route appeared to have a better reduction of tumor volume. It is also noteworthy that HJC0416 does not show significant signs of toxicity at a dose of 100 mg/kg^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice with MDA-MB-231 cells ^[1]
---------------	---

Dosage:	10 mg/kg (i.p.); 100 mg/kg (oral)
---------	-----------------------------------

Administration:	Intraperitoneal injection, 7 days; oral administration, 14 days
-----------------	---

Result:	Exhibited antitumor effects in the MDA-MB-231 triple-negative breast cancer murine xenograft model.
---------	---

REFERENCES

[1]. Haijun Chen, et al. Discovery of Potent Anticancer Agent HJC0416, an Orally Bioavailable Small Molecule Inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3). *Eur J Med Chem.* 2014 Jul 23;82:195-203.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA